G1 Therapeutics Inc (GTHX) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of cancer. The company's lead product candidate, trilaciclib, is a first-in-class intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor that is designed to preserve hematopoietic stem and progenitor cells and enhance immune system function during chemotherapy. Trilaciclib is being evaluated in clinical trials for the treatment of small cell lung cancer, triple-negative breast cancer, and colorectal cancer. G1 Therapeutics is also developing other product candidates, including rintodestrant, a selective estrogen receptor degrader for the treatment of ER+/HER2- breast cancer, and G1T48, an oral selective estrogen receptor degrader for the treatment of advanced or metastatic breast cancer. The company is headquartered in Research Triangle Park, North Carolina, and as of September 2021, had a market capitalization of approximately $2.2 billion.
G1 Therapeutics Inc (GTHX) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of cancer. The company's lead product candidate, trilaciclib, is a first-in-class intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor that is designed to preserve hematopoietic stem and progenitor cells and enhance immune system function during chemotherapy. Trilaciclib is being evaluated in clinical trials for the treatment of small cell lung cancer, triple-negative breast cancer, and colorectal cancer. G1 Therapeutics is also developing other product candidates, including rintodestrant, a selective estrogen receptor degrader for the treatment of ER+/HER2- breast cancer, and G1T48, an oral selective estrogen receptor degrader for the treatment of advanced or metastatic breast cancer. The company is headquartered in Research Triangle Park, North Carolina, and as of September 2021, had a market capitalization of approximately $2.2 billion.